Cynata Therapeutics (CYP.AX) Stock Price
Cynata Therapeutics Price
Over the last 19 years Cynata Therapeutics grew revenue by 11.7% annually, reaching 1.71 M AUD. For Cynata Therapeutics, the net margin of -531.0% is down versus -70.1% a few years ago.
Cynata Therapeutics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cynata Therapeutics business model & stock analysis
Frequently asked questions about Cynata Therapeutics
Cynata Therapeutics Ltd is a biotechnology company with a unique business model focused on regenerative medicine. The company specializes in the development and commercialization of a proprietary stem cell technology known as Cymerus™. This technology enables large-scale production of high-quality mesenchymal stem cells (MSCs) from a single donor, eliminating the need for multiple donors. Cynata Therapeutics aims to utilize this technology to address a wide range of therapeutic applications, including graft-versus-host disease, cardiovascular diseases, osteoarthritis, and respiratory disorders. By leveraging their innovative Cymerus™ platform, Cynata Therapeutics strives to revolutionize the way regenerative medicine is approached and provide effective treatments for various medical conditions.
Cynata Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Cynata Therapeutics Ltd in the market are Mesoblast Limited, Pluristem Therapeutics Inc., and Athersys Inc.
Cynata Therapeutics Ltd is an Australian-based biotechnology company specializing in regenerative medicine. Established in 2011, the company focuses on developing innovative therapeutic stem cell products for a broad range of medical conditions. With a strong emphasis on clinical advancements, Cynata Therapeutics has made significant progress in stem cell research and development. Boasting a team of accomplished scientists and researchers, the company's revolutionary Cymerus™ platform technology allows for large-scale production of high-quality mesenchymal stem cells. Cynata Therapeutics is committed to transforming healthcare through their groundbreaking stem cell technology, offering hope for the treatment of various diseases and conditions.
Cynata Therapeutics Ltd has achieved several significant milestones. Firstly, the company successfully developed and patented a game-changing Cymerus™ technology, which enables the production of high-quality mesenchymal stem cells. Additionally, they conducted successful preclinical trials, demonstrating the potential of Cymerus™ MSCs in various therapeutic applications. Cynata Therapeutics Ltd also achieved a major milestone by conducting the world's first clinical trial using an allogeneic mesenchymal stem cell product derived from a single induced pluripotent stem cell donor. Furthermore, the company secured collaboration and licensing agreements with renowned pharmaceutical companies, further validating their technology and expanding their reach in the global market.
Cynata Therapeutics Ltd is primarily present in Australia, where it is headquartered.
Cynata Therapeutics Ltd represents values of innovation, collaboration, and dedication. With a strong corporate philosophy focused on developing novel stem cell therapies, Cynata is committed to improving patient outcomes and addressing unmet medical needs. As a leading biotechnology company, Cynata operates with a passion for scientific excellence and a drive to deliver transformative treatments. By harnessing the unique capabilities of its proprietary Cymerus™ technology, the company aims to revolutionize the field of regenerative medicine. Cynata Therapeutics Ltd prioritizes ethical practices, community engagement, and the pursuit of groundbreaking advancements to shape the future of healthcare.
5 analysts currently rate the Cynata Therapeutics stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Cynata Therapeutics share trades at 0.01 EUR (0.01 AUD).
Cynata Therapeutics Ltd is an Australian biotechnology company specializing in the development of cellular therapies for the treatment of various diseases. The company's business model is based on the use of its proprietary mesenchymal stem cell technology, which enables a wide range of potential applications. Cynata Therapeutics has divisions focusing on regenerative medicine, specifically therapies for tissue regeneration after injuries or diseases, and immunotherapy, aiming to improve the body's immune system for more effective cancer and disease treatment. The company also offers various products based on its mesenchymal stem cell technology for research and development in cell-based therapies. Cynata Therapeutics operates through innovation, research, and development, continually investing in its scientists and research partners to improve its technology and discover new applications. Additionally, it collaborates with leading researchers and institutions to share findings and promote therapy development. The company also pursues international cooperation and partnerships to market and utilize its technology and products globally, recently partnering with Fujifilm for distribution in Japan and other Asian markets. In summary, Cynata Therapeutics provides a wide range of cellular therapies and products based on its mesenchymal stem cell technology, aiming to improve patient care and offer solutions for serious and life-threatening diseases. With its strong research efforts and international focus, the company will continue to play a leading role in the cellular therapy market and establish itself in the field of regenerative medicine and immunotherapy.
The revenue of Cynata Therapeutics is 1.71 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Cynata Therapeutics is -9.09 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cynata Therapeutics is currently -0.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cynata Therapeutics stock.
The price-to-sales ratio (P/S) of Cynata Therapeutics is currently 1.53. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cynata Therapeutics stock.
The Eulerpool Quality Score for Cynata Therapeutics is 2/10.
The ISIN of Cynata Therapeutics is AU000000CYP7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cynata Therapeutics is A1W8VE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cynata Therapeutics is CYP.AX. The ticker symbol is used to trade Cynata Therapeutics shares on the stock exchange.
Cynata Therapeutics stock
Cynata Therapeutics Peer Group
Cynata Therapeutics FIGI
All fundamentals and in-depth analysis of Cynata Therapeutics
Our stock analysis for Cynata Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cynata Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.